OBJECTIVE To review all currently published drug-drug interaction studies with the HIV-integrase inhibitor raltegravir. METHODS A PubMed search was conducted for all published reports up to August 1, 2009 as well as a review of updated European and US Prescriber's Information (EMEA and FDA) and abstracts from recent international scientific meetings. RESULTS A total of 14 drug-drug interact...

voriconazole is an antifungal triazole, approved for management of invasive fungal diseases in patients. it is absorbed during two hours and its serum levels will be above 90%, based on the underlying factors, when the drug is administered orally. voriconazole shows a propotional increase in an area under the plasma concentration-time curve (auc), with increasing dose. plasma protein binding of...

Many patients treated with imatinib, used in cancer treatment, are using several other drugs that could interact with imatinib. Our aim was to study all the drug-drug interactions (DDIs) observed in patients treated with imatinib.We performed 2 observational studies, between the 1st January 2012 and the 31st August 2015 in the Midi-Pyrénées area (South Western France), using the French health i...

Protein Binding One of the most important factors in drug-drug interactions is the plasma protein concentration, specifically albumin. Albumin is the major protein responsible for binding acidic drugs such as warfarin, NSAIDS and anticonvulsants. Decreases in albumin level, which are commonly seen with critical illness, can lead to an excess of unbound, and therefore more active, drug. Alpha1-a...

Background: Drug-drug interactions (DDIs) may often lead to preventable adverse drug events and health damage. Particularly in hospitals, this might be an important factor as multiple drug therapies are common. The objective of this study was to identify the frequency and levels of potential DDIs in internal medicine wards in an Iranian university hospital. Methods: A cross-sectional study...

Patient noncompliance to current tuberculosis (TB) therapy owing to multidrug administration daily leads to treatment failure and emergence of multidrug resistant and extensively drug resistant TB. To avoid the daily dosing, application of nanotechnology is the only viable solution by virtue of sustained release of drugs. Other potential advantages of the system include the possibility of selec...